1. Burova E, Hermann A, Waite J, et al. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Mol Cancer Ther. 2017;16(5):861–70.
2. Regeneron Pharmaceuticals. Libtayo (cemiplimab): US prescribing information. 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
. Accessed 2018.
3. FDA. FDA approves first treatment for advanced form of the second most common skin cancer. [Media release 28 Sep 2018].
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622044.htm
.
4. Regeneron Pharmaceuticals. Regeneron and Sanofi launch major new immuno-oncology collaboration. [Media release 28 Jul 2015].
http://www.regeneron.com
.
5. Sanofi. Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs. [Media release 8 Jan 2018].
http://www.sanofi.com
.